Jessica Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jessica Cao has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Michael Henry Brent
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada; Department of Ophthalmology, Toronto Western Hospital, Toronto, ON, Canada
2 shared publications - Tina Felfeli
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada
2 shared publications Adeteju Ogunbameru
University of Toronto
1 shared publication- Angela Y. Zhu
Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA
1 shared publication Brittany Chang-Kit
University of Toronto
1 shared publicationDaniel J. Weisbrod
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ont.; Department of Ophthalmology, Sunnybrook Health Sciences Centre, Toronto, Ont
1 shared publication
Latest Publications
- 16 December 2022
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (2) , 96-101
Ganglion cell complex changes in wet AMD patients treated with anti-VEGF intravitreal injections according to a treat-and-extend protocol
- 16 December 2022
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 59 (2) , 96-101
Ganglion cell complex changes in wet AMD patients treated with anti-VEGF intravitreal injections according to a treat-and-extend protocol
- 1 December 2022
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 57 (6) , 394-401
University of Toronto's redesigned ophthalmology curriculum and eye dissection lab
- 1 December 2022
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 57 (6) , 394-401
University of Toronto's redesigned ophthalmology curriculum and eye dissection lab
- Open Access
- 1 February 2022
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 57 (1) , e24-e27
Neurotrophic keratopathy following laser retinopexy for high myopia in an autistic child
- 1 February 2022
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 57 (1) , e24-e27
Open AccessNeurotrophic keratopathy following laser retinopexy for high myopia in an autistic child
- 1 February 2022
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 46 (1) , 26-31
Sociodemographics Associated With Risk of Diabetic Retinopathy Detected by Tele-Ophthalmology: 5-Year Results of the Toronto Tele-Retinal Screening Program
- 1 February 2022
- Published by Elsevier in Canadian Journal of Diabetes
- Vol. 46 (1) , 26-31
Sociodemographics Associated With Risk of Diabetic Retinopathy Detected by Tele-Ophthalmology: 5-Year Results of the Toronto Tele-Retinal Screening Program
- Open Access
- 18 January 2022
- Published by Springer Nature in Research Square
Protocol for a systematic review and meta-analysis of the diagnostic accuracy of artificial intelligence for grading of ophthalmology imaging modalities
BackgroundWith the rise of artificial intelligence (AI) in ophthalmology, the need to define its diagnostic accuracy is increasingly important. The review aims to elucidate the diagnostic accuracy of AI algorithms in screening for all ophthalmic conditions in patient care settings that involve digital imaging modalities, using the reference standard of human graders.MethodsThis is a systematic review and meta-analysis. A literature search will be conducted on Ovid Medline, Ovid EMBASE, and Wiley Cochrane CENTRAL from January 1, 2000 to December 20, 2021. Studies will be selected via screening titles and abstracts, followed by full-text screening. Articles that compare the results of AI-graded ophthalmic images with results from human graders as a reference standard will be included. Systematic review software DistillerSR will be used to automate part of the screening process as an adjunct to human reviewers. After full text screening, data will be extracted from each study via the categories of study characteristics, patient information, AI methods, intervention, and outcomes. Risk of bias will be scored using Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) by two trained independent reviewers. Disagreements at any step will be addressed by a third adjudicator. Study results will include summary receiver operating characteristic (sROC) curve plots as well as pooled sensitivity and specificity of artificial intelligence for detection of any ophthalmic conditions based on imaging modalities compared to the reference standard. Statistics will be calculated in R statistical software.DiscussionThis study will provide novel insights on diagnostic accuracy of AI in new domains of ophthalmology that have not been previously studied. The protocol also outlines the use of an AI-based software to assist article screening, which may serve as a reference for improving efficiency and accuracy of future large systematic reviews.Systematic Review Registration: This study is registered on PROSPERO (CRD42021274441).
- 18 January 2022
- Published by Springer Nature in Research Square
Open AccessProtocol for a systematic review and meta-analysis of the diagnostic accuracy of artificial intelligence for grading of ophthalmology imaging modalities
BackgroundWith the rise of artificial intelligence (AI) in ophthalmology, the need to define its diagnostic accuracy is increasingly important. The review aims to elucidate the diagnostic accuracy of AI algorithms in screening for all ophthalmic conditions in patient care settings that involve digital imaging modalities, using the reference standard of human graders.MethodsThis is a systematic review and meta-analysis. A literature search will be conducted on Ovid Medline, Ovid EMBASE, and Wiley Cochrane CENTRAL from January 1, 2000 to December 20, 2021. Studies will be selected via screening titles and abstracts, followed by full-text screening. Articles that compare the results of AI-graded ophthalmic images with results from human graders as a reference standard will be included. Systematic review software DistillerSR will be used to automate part of the screening process as an adjunct to human reviewers. After full text screening, data will be extracted from each study via the categories of study characteristics, patient information, AI methods, intervention, and outcomes. Risk of bias will be scored using Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) by two trained independent reviewers. Disagreements at any step will be addressed by a third adjudicator. Study results will include summary receiver operating characteristic (sROC) curve plots as well as pooled sensitivity and specificity of artificial intelligence for detection of any ophthalmic conditions based on imaging modalities compared to the reference standard. Statistics will be calculated in R statistical software.DiscussionThis study will provide novel insights on diagnostic accuracy of AI in new domains of ophthalmology that have not been previously studied. The protocol also outlines the use of an AI-based software to assist article screening, which may serve as a reference for improving efficiency and accuracy of future large systematic reviews.Systematic Review Registration: This study is registered on PROSPERO (CRD42021274441).
- Open Access
- 1 March 2018
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 13, 1633-1642
Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma
Background: Circulating tumor cells (CTCs) detection, an approach considered to be “liquid biopsy”, is a potential alternative method in clinical use for early diagnosis of solid tumor progression. Methods: In this study, we developed a poly (lactic-co-glycolic acid) (PLGA) – nanofiber (PN)-NanoVelcro chip as an efficient device for simple and rapid capture of CTCs from peripheral blood. We evaluated the device performance by assessing the capture efficiency and purity. Single CTC was isolated via laser microdissection system for subsequent genetic analysis, with an aim to find the concordance of epidermal growth factor receptor (EGFR) mutations between tumor tissue and CTCs. Results: PN-NanoVelcro chip exhibits great performance in capture efficiency and high purity. The genetic analysis results showed that most EGFR mutation in tumor tissue could also be detected in CTCs. Conclusion: Compared to computed tomography image results, CTC detection can be implemented throughout the course of diseases and provides an accurate and earlier diagnosis of tumor progression, which make it possible for patients to acquire suitable and timely treatment.
- 1 March 2018
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 13, 1633-1642
Open AccessPolymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma
Background: Circulating tumor cells (CTCs) detection, an approach considered to be “liquid biopsy”, is a potential alternative method in clinical use for early diagnosis of solid tumor progression. Methods: In this study, we developed a poly (lactic-co-glycolic acid) (PLGA) – nanofiber (PN)-NanoVelcro chip as an efficient device for simple and rapid capture of CTCs from peripheral blood. We evaluated the device performance by assessing the capture efficiency and purity. Single CTC was isolated via laser microdissection system for subsequent genetic analysis, with an aim to find the concordance of epidermal growth factor receptor (EGFR) mutations between tumor tissue and CTCs. Results: PN-NanoVelcro chip exhibits great performance in capture efficiency and high purity. The genetic analysis results showed that most EGFR mutation in tumor tissue could also be detected in CTCs. Conclusion: Compared to computed tomography image results, CTC detection can be implemented throughout the course of diseases and provides an accurate and earlier diagnosis of tumor progression, which make it possible for patients to acquire suitable and timely treatment.